The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition

Current Topics in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 95-114

  Kaoukis, Andreas ^a   Deftereos, Spyridon ^a   Raisakis, Konstantinos ^a   Giannopoulos, Georgios ^a   Bouras, Georgios ^a   Panagopoulou, Vasiliki ^a   Papoutsidakis, Nikolaos ^a   Cleman, Michael W ^b   Stefanadis, Christodoulos ^c  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Arterial hypertension; Atherosclerosis; Bosentan; Cardiovascular disease; Coronary artery disease; Endothelin; Heart failure; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRASENTAN; BOSENTAN; CLAZOSENTAN; DAGLUTRIL; DARUSENTAN; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENRASENTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; MACITENTAN; MEMBRANE METALLOENDOPEPTIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TEZOSENTAN; TRANDOLAPRIL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EISENMENGER COMPLEX; ESSENTIAL HYPERTENSION; FLUSHING; GENE EXPRESSION; HEADACHE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; LEG EDEMA; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); NONHUMAN; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT;

ANIMALS; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ENDOTHELIN-1; ENDOTHELINS; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PREDICTIVE VALUE OF TESTS; PYRIDAZINES; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 84877814873     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313020003     Document Type: Review

References (222)

1. Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K.; Masaki, T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature, 1990, 348, 732-735.
2. Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K.; Masaki, T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A, 1989, 86, 2863-2867.
3. Takahashi, M.; Matsushita, Y.; Iijima, Y.; Tanzawa, K. Purification and characterization of endothelin-converting enzyme from rat lung. J Biol Chem, 1993, 268, 21394-21398.
4. Inagaki, M.; Hashimoto, K.; Takahashi, H.; Takeshita, K. [Blood endothelin concentration from umbilical cord and preterm baby: perinatal factor and cranial untrasonography in the cases of abnormally high concentration]. No To Hattatsu, 1993, 25, 385-387.
5. Takahashi, K.; Katoh, T.; Fukunaga, M.; Badr, K. F. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endothelin. Am Heart J, 1993, 125, 609-619.
6. Xu, D.; Emoto, N.; Giaid, A.; Slaughter, C.; Kaw, S.; deWit, D.; Yanagisawa, M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell, 1994, 78, 473-485.
7. Emoto, N.; Yanagisawa, M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem, 1995, 270, 15262-15268.
8. Levin, E. R. Endothelins as cardiovascular peptides. Am J Nephrol, 1996, 16, 246-251.
9. Nunez, D. J.; Brown, M. J.; Davenport, A. P.; Neylon, C. B.; Schofield, J. P.; Wyse, R. K. Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest, 1990, 85, 1537-1541.
10. Ohkita, M.; Tawa, M.; Kitada, K.; Matsumura, Y. Pathophysiological roles of endothelin receptors in cardiovascular diseases. J Pharmacol Sci, 2012, 119, 302-313.
11. Wilson, D. B.; Dorfman, D. M.; Orkin, S. H. A nonerythroid GATA-binding protein is required for function of the human preproendothelin-1 promoter in endothelial cells. Mol Cell Biol, 1990, 10, 4854-4862.
12. Hu, J.; Discher, D. J.; Bishopric, N. H.; Webster, K. A. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun, 1998, 245, 894-899.
13. Denault, J. B.; Claing, A.; D'Orleans-Juste, P.; Sawamura, T.; Kido, T.; Masaki, T.; Leduc, R. Processing of proendothelin-1 by human furin convertase. FEBS Lett, 1995, 362, 276-280.
14. Hasegawa, H.; Hiki, K.; Sawamura, T.; Aoyama, T.; Okamoto, Y.; Miwa, S.; Shimohama, S.; Kimura, J.; Masaki, T. Purification of a novel endothelin-converting enzyme specific for big endothelin-3. FEBS Lett, 1998, 428, 304-308.
15. D'Orleans-Juste, P.; Plante, M.; Honore, J. C.; Carrier, E.; Labonte, J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol, 2003, 81, 503-510.
16. Hemsen, A.; Larsson, O.; Lundberg, J. M. Characteristics of endothelin A and B binding sites and their vascular effects in pig peripheral tissues. Eur J Pharmacol, 1991, 208, 313-322.
17. Haynes, W. G.; Webb, D. J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, 1994, 344, 852-854.
18. Russell, F. D.; Skepper, J. N.; Davenport, A. P. Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res, 1998, 83, 314-321.
19. Johnstrom, P.; Fryer, T. D.; Richards, H. K.; Harris, N. G.; Barret, O.; Clark, J. C.; Pickard, J. D.; Davenport, A. P. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol, 2005, 144, 115-122.
20. Strachan, F. E.; Spratt, J. C.; Wilkinson, I. B.; Johnston, N. R.; Gray, G. A.; Webb, D. J. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension, 1999, 33, 581-585.
21. Iglarz, M.; Binkert, C.; Morrison, K.; Fischli, W.; Gatfield, J.; Treiber, A.; Weller, T.; Bolli, M. H.; Boss, C.; Buchmann, S.; Capeleto, B.; Hess, P.; Qiu, C.; Clozel, M. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther, 2008, 327, 736-745.
22. Dimitrijevic, I.; Edvinsson, M. L.; Chen, Q.; Malmsjo, M.; Kimblad, P. O.; Edvinsson, L. Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease. BMC Cardiovasc Disord, 2009, 9, 40.
23. Bourque, S. L.; Davidge, S. T.; Adams, M. A. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol, 2011, 300, R1288-1295.
24. Jae, H. S.; Winn, M.; von Geldern, T. W.; Sorensen, B. K.; Chiou, W. J.; Nguyen, B.; Marsh, K. C.; Opgenorth, T. J. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 5. Highly selective, potent, and orally active ET(A) antagonists. J Med Chem, 2001, 44, 3978-3984.
25. Ishikawa, K.; Ihara, M.; Noguchi, K.; Mase, T.; Mino, N.; Saeki, T.; Fukuroda, T.; Fukami, T.; Ozaki, S.; Nagase, T.; et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A, 1994, 91, 4892-4896.
26. Clozel, M.; Breu, V.; Gray, G. A.; Kalina, B.; Loffler, B. M.; Burri, K.; Cassal, J. M.; Hirth, G.; Muller, M.; Neidhart, W.; et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther, 1994, 270, 228-235.
27. Simonson, M. S.; Dunn, M. J. Cellular signaling by peptides of the endothelin gene family. FASEB J, 1990, 4, 2989-3000.
28. De Mey, J. G.; Compeer, M. G.; Lemkens, P.; Meens, M. J. ETA-receptor antagonists or allosteric modulators? Trends Pharmacol Sci, 2011, 32, 345-351.
29. Evans, N. J.; Walker, J. W. Endothelin receptor dimers evaluated by FRET, ligand binding, and calcium mobilization. Biophys J, 2008, 95, 483-492.
30. Zeng, C.; Asico, L. D.; Yu, C.; Villar, V. A.; Shi, W.; Luo, Y.; Wang, Z.; He, D.; Liu, Y.; Huang, L.; Yang, C.; Wang, X.; Hopfer, U.; Eisner, G. M.; Jose, P. A. Renal D3 dopamine receptor stimulation induces natriuresis by endothelin B receptor interactions. Kidney Int, 2008, 74, 750-759.
31. Lerman, A.; Edwards, B. S.; Hallett, J. W.; Heublein, D. M.; Sandberg, S. M.; Burnett, J. C., Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med, 1991, 325, 997-1001.
32. Suzuki, N.; Matsumoto, H.; Kitada, C.; Masaki, T.; Fujino, M. A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods, 1989, 118, 245-250.
33. Saito, Y.; Nakao, K.; Itoh, H.; Yamada, T.; Mukoyama, M.; Arai, H.; Hosoda, K.; Shirakami, G.; Suga, S.; Jougasaki, M.; et al. Endothelin in human plasma and culture medium of aortic endothelial cells--detection and characterization with radioimmunoassay using monoclonal antibody. Biochem Biophys Res Commun, 1989, 161, 320-326.
34. Suzuki, N.; Matsumoto, H.; Miyauchi, T.; Kitada, C.; Tsuda, M.; Goto, K.; Masaki, T.; Fujino, M. Sandwich-enzyme immunoassays for endothelin family peptides. J Cardiovasc Pharmacol, 1991, 17 Suppl 7, S420-422.
35. Weitzberg, E.; Ahlborg, G.; Lundberg, J. M. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun, 1991, 180, 1298-1303.
36. de Nucci, G.; Thomas, R.; D'Orleans-Juste, P.; Antunes, E.; Walder, C.; Warner, T. D.; Vane, J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A, 1988, 85, 9797-9800.
37. Ferro, C. J.; Spratt, J. C.; Haynes, W. G.; Webb, D. J. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation, 1998, 97, 2323-2330.
38. Rossi, G. P.; Seccia, T. M.; Albertin, G.; Pessina, A. C. Measurement of endothelin: clinical and research use. Ann Clin Biochem, 2000, 37 (Pt 5), 608-626.
39. Rolinski, B.; Sadri, I.; Bogner, J.; Goebel, F. D. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med (Berl), 1994, 194, 9-24.
40. Matsumoto, H.; Suzuki, N.; Kitada, C.; Fujino, M. Endothelin family peptides in human plasma and urine: their molecular forms and concentrations. Peptides, 1994, 15, 505-510.
41. Hemsen, A.; Ahlborg, G.; Ottosson-Seeberger, A.; Lundberg, J. M. Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept, 1995, 55, 287-297.
42. Nakano, A.; Kishi, F.; Minami, K.; Wakabayashi, H.; Nakaya, Y.; Kido, H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol, 1997, 159, 1987-1992.
43. Papassotiriou, J.; Morgenthaler, N. G.; Struck, J.; Alonso, C.; Bergmann, A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem, 2006, 52, 1144-1151.
44. Struck, J.; Morgenthaler, N. G.; Bergmann, A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides, 2005, 26, 2482-2486.
45. Jankowska, E. A.; Filippatos, G. S.; von Haehling, S.; Papassotiriou, J.; Morgenthaler, N. G.; Cicoira, M.; Schefold, J. C.; Rozentryt, P.; Ponikowska, B.; Doehner, W.; Banasiak, W.; Hartmann, O.; Struck, J.; Bergmann, A.; Anker, S. D.; Ponikowski, P. Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal pro-endothelin-1. PLoS One, 2011, 6, e14506.
46. Remuzzi, G.; Perico, N.; Benigni, A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov, 2002, 1, 986-1001.
47. Kenyon, K. W.; Nappi, J. M. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother, 2003, 37, 1055-1062.
48. Channick, R. N.; Simonneau, G.; Sitbon, O.; Robbins, I. M.; Frost, A.; Tapson, V. F.; Badesch, D. B.; Roux, S.; Rainisio, M.; Bodin, F.; Rubin, L. J. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet, 2001, 358, 1119-1123.
49. Williamson, D. J.; Wallman, L. L.; Jones, R.; Keogh, A. M.; Scroope, F.; Penny, R.; Weber, C.; Macdonald, P. S. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation, 2000, 102, 411-418.
50. Kim, H.; Yung, G. L.; Marsh, J. J.; Konopka, R. G.; Pedersen, C. A.; Chiles, P. G.; Morris, T. A.; Channick, R. N. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur Respir J, 2000, 15, 640-648.
51. Holm, P.; Liska, J.; Clozel, M.; Franco-Cereceda, A. The endothelin antagonist bosentan: hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs. J Thorac Cardiovasc Surg, 1996, 112, 890-897.
52. Galie, N.; Hoeper, M. M.; Humbert, M.; Torbicki, A.; Vachiery, J. L.; Barbera, J. A.; Beghetti, M.; Corris, P.; Gaine, S.; Gibbs, J. S.; Gomez-Sanchez, M. A.; Jondeau, G.; Klepetko, W.; Opitz, C.; Peacock, A.; Rubin, L.; Zellweger, M.; Simonneau, G. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J, 2009, 30, 2493-2537.
53. Humbert, M.; Segal, E. S.; Kiely, D. G.; Carlsen, J.; Schwierin, B.; Hoeper, M. M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J, 2007, 30, 338-344.
54. McGoon, M. D.; Frost, A. E.; Oudiz, R. J.; Badesch, D. B.; Galie, N.; Olschewski, H.; McLaughlin, V. V.; Gerber, M. J.; Dufton, C.; Despain, D. J.; Rubin, L. J. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest, 2009, 135, 122-129.
55. Bohm, F.; Pernow, J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res, 2007, 76, 8-18.
56. Pernow, J.; Shemyakin, A.; Bohm, F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci, 2012, 91, 507-516.
57. Liu, H.; Peng, Y.; Liu, F.; Liu, Y.; Ouyang, L.; Xiao, W.; Cheng, M.; Chen, X.; Gao, L. Correlation between endothelin-1 and atherosclerosis in chronic hemodialysis patients. J Nephrol, 2010, 23, 593-602.
58. Matsuyama, K.; Yasue, H.; Okumura, K.; Saito, Y.; Nakao, K.; Shirakami, G.; Imura, H. Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina. Am J Cardiol, 1991, 68, 991-995.
59. Miyauchi, T.; Yanagisawa, M.; Tomizawa, T.; Sugishita, Y.; Suzuki, N.; Fujino, M.; Ajisaka, R.; Goto, K.; Masaki, T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet, 1989, 2, 53-54.
60. Malatino, L. S.; Grassi, R.; Stancanelli, B.; Polizzi, G.; Leonardi, C.; Tamburino, C.; Tamburino, G. Release of immunoreactive endothelin from the heart during percutaneous transluminal coronary angioplasty. Am Heart J, 1993, 126, 700-702.
61. Lerman, A.; Holmes, D. R., Jr.; Bell, M. R.; Garratt, K. N.; Nishimura, R. A.; Burnett, J. C., Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation, 1995, 92, 2426-2431.
62. Lerman, A.; Webster, M. W.; Chesebro, J. H.; Edwards, W. D.; Wei, C. M.; Fuster, V.; Burnett, J. C., Jr. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation, 1993, 88, 2923-2928.
63. Rossi, G. P.; Colonna, S.; Pavan, E.; Albertin, G.; Della Rocca, F.; Gerosa, G.; Casarotto, D.; Sartore, S.; Pauletto, P.; Pessina, A. C. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation, 1999, 99, 1147-1155.
64. Tousoulis, D.; Antoniades, C.; Marinou, K.; Vasiliadou, C.; Bouras, G.; Stefanadi, E.; Latsios, G.; Siasos, G.; Toutouzas, K.; Stefanadis, C. Methionine-loading rapidly impairs endothelial function, by mechanisms independent of endothelin-1: evidence for an association of fasting total homocysteine with plasma endothelin-1 levels. J Am Coll Nutr, 2008, 27, 379-386.
65. Tousoulis, D.; Bouras, G.; Antoniades, C.; Marinou, K.; Miliou, A.; Papageorgiou, N.; Chatzis, G.; Tentolouris, C.; Tsioufis, C.; Stefanadis, C. The activation of endothelin-1 pathway during methionine-induced homocysteinemia mediates endothelial dysfunction in hypertensive individuals. J Hypertens, 2010, 28, 925-930.
66. Haug, C.; Voisard, R.; Lenich, A.; Baur, R.; Hoher, M.; Osterhues, H.; Hannekum, A.; Vogel, U.; Mattfeldt, T.; Hombach, V.; Grunert, A. Increased endothelin release by cultured human smooth muscle cells from atherosclerotic coronary arteries. Cardiovasc Res, 1996, 31, 807-813.
67. Maguire, J. J.; Davenport, A. P. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br J Pharmacol, 1998, 125, 238-240.
68. Jin, Z.; Luxiang, C.; Huadong, Z.; Zhiqiang, X.; Lihua, H.; Huiyun, L. C-338A polymorphism of the endothelin-converting enzyme-1 gene and the susceptibility to carotid atherosclerosis. Microvasc Res, 2009, 78, 128-131.
69. Simeone, S. M.; Li, M. W.; Paradis, P.; Schiffrin, E. L. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiol Genomics, 2011, 43, 148-160.
70. Iwasa, S.; Fan, J.; Shimokama, T.; Nagata, M.; Watanabe, T. Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis, 1999, 146, 93-100.
71. Best, P. J.; Lerman, L. O.; Romero, J. C.; Richardson, D.; Holmes, D. R., Jr.; Lerman, A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol, 1999, 19, 2769-2775.
72. Niemann, B.; Rohrbach, S.; Catar, R. A.; Muller, G.; Barton, M.; Morawietz, H. Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells. Biochem Biophys Res Commun, 2005, 334, 747-753.
73. Morawietz, H.; Duerrschmidt, N.; Niemann, B.; Galle, J.; Sawamura, T.; Holtz, J. Induction of the oxLDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem Biophys Res Commun, 2001, 284, 961-965.
74. Rosenson, R. S. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs, 2001, 1, 411-420.
75. Settergren, M.; Bohm, F.; Ryden, L.; Pernow, J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J, 2008, 29, 1753-1760.
76. Ergul, A.; Johansen, J. S.; Stromhaug, C.; Harris, A. K.; Hutchinson, J.; Tawfik, A.; Rahimi, A.; Rhim, E.; Wells, B.; Caldwell, R. W.; Anstadt, M. P. Vascular dysfunction of venous bypass conduits is mediated by reactive oxygen species in diabetes: role of endothelin-1. J Pharmacol Exp Ther, 2005, 313, 70-77.
77. Katayama, T.; Yano, K.; Nakashima, H.; Takagi, C.; Honda, Y.; Suzuki, S.; Iwasaki, Y. Clinical significance of acute-phase endothelin-1 in acute myocardial infarction patients treated with direct coronary angioplasty. Circ J, 2005, 69, 654-658.
78. Eitel, I.; Nowak, M.; Stehl, C.; Adams, V.; Fuernau, G.; Hildebrand, L.; Desch, S.; Schuler, G.; Thiele, H. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. Am Heart J, 2010, 159, 882-890.
79. Freixa, X.; Heras, M.; Ortiz, J. T.; Argiro, S.; Guasch, E.; Doltra, A.; Jimenez, M.; Betriu, A.; Masotti, M. Usefulness of endothelin-1 assessment in acute myocardial infarction. Rev Esp Cardiol, 2011, 64, 105-110.
80. Wu, E.; Izquierdo Gomez, M. M. Cardiac magnetic resonance imaging and endothelin-1: a step forward in the detection of microvascular obstruction. Rev Esp Cardiol, 2011, 64, 89-91.
81. Freixa, X.; Masotti, M.; Palomo, M.; Diaz-Ricart, M.; Escolar, G.; Guasch, E.; Regueiro, A.; Jimenez, M.; Betriu, A.; Heras, M. Endothelin-1 levels predict endothelial progenitor cell mobilization after acute myocardial infarction. Microvasc Res, 2011, 82, 177-181.
82. Wojakowski, W.; Tendera, M.; Zebzda, A.; Michalowska, A.; Majka, M.; Kucia, M.; Maslankiewicz, K.; Wyderka, R.; Krol, M.; Ochala, A.; Kozakiewicz, K.; Ratajczak, M. Z. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J, 2006, 27, 283-289.
83. Khan, S. Q.; Dhillon, O.; Struck, J.; Quinn, P.; Morgenthaler, N. G.; Squire, I. B.; Davies, J. E.; Bergmann, A.; Ng, L. L. C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J, 2007, 154, 736-742.
84. Stewart, D. J.; Kubac, G.; Costello, K. B.; Cernacek, P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol, 1991, 18, 38-43.
85. Sabatine, M. S.; Morrow, D. A.; de Lemos, J. A.; Omland, T.; Sloan, S.; Jarolim, P.; Solomon, S. D.; Pfeffer, M. A.; Braunwald, E. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation, 2012, 125, 233-240.
86. Yokoi, K.; Adachi, H.; Hirai, Y.; Enomoto, M.; Fukami, A.; Ogata, K.; Tsukagawa, E.; Kasahara, A.; Imaizumi, T. Plasma endothelin-1 level is a predictor of 10-year mortality in a general population: the Tanushimaru study. Circ J, 2012, 76, 2779-2784.
87. Schnabel, R. B.; Wild, P. S.; Schulz, A.; Zeller, T.; Sinning, C. R.; Wilde, S.; Kunde, J.; Lubos, E.; Lackner, K. J.; Warnholtz, A.; Gori, T.; Blankenberg, S.; Munzel, T. Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study. Hypertension, 2012, 60, 288-295.
88. de Haro Miralles, J.; Gonzalez, A. F.; Varela Casariego, C.; Garcia, F. A. Onset of peripheral arterial disease: role of endothelin in endothelial dysfunction. Interact Cardiovasc Thorac Surg, 2010, 10, 760-765.
89. Reriani, M.; Raichlin, E.; Prasad, A.; Mathew, V.; Pumper, G. M.; Nelson, R. E.; Lennon, R.; Rihal, C.; Lerman, L. O.; Lerman, A. Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation, 2010, 122, 958-966.
90. Bohm, F.; Beltran, E.; Pernow, J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J Intern Med, 2005, 257, 263-271.
91. Climent, B.; Fernandez, N.; Sanz, E.; Sanchez, A.; Monge, L.; Garcia-Villalon, A. L.; Dieguez, G. Enhanced response of pig coronary arteries to endothelin-1 after ischemia-reperfusion. Role of endothelin receptors, nitric oxide and prostanoids. Eur J Pharmacol, 2005, 524, 102-110.
92. Gonon, A. T.; Erbas, D.; Broijersen, A.; Valen, G.; Pernow, J. Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol, 2004, 286, H1767-1774.
93. Pernow, J.; Wang, Q. D. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res, 1997, 33, 518-526.
94. Adlbrecht, C.; Andreas, M.; Redwan, B.; Distelmaier, K.; Mascherbauer, J.; Kaider, A.; Wolzt, M.; Tilea, I. A.; Neunteufl, T.; Delle-Karth, G.; Maurer, G.; Lang, I. M. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention, 2012, 7, 1386-1395.
95. Takase, H.; Sugiyama, M.; Nakazawa, A.; Toriyama, T.; Hayashi, K.; Goto, T.; Sato, K.; Ikeda, K.; Ueda, R.; Dohi, Y. Increased endogenous endothelin-1 in coronary circulation is associated with restenosis after coronary angioplasty. Can J Cardiol, 2003, 19, 902-906.
96. Shirai, N.; Naruko, T.; Ohsawa, M.; Ikura, Y.; Sugama, Y.; Hirayama, M.; Kitabayashi, C.; Ehara, S.; Inoue, T.; Itoh, A.; Haze, K.; Tanzawa, K.; Yoshiyama, M.; Yoshikawa, J.; Ueda, M. Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans. J Hypertens, 2006, 24, 711-721.
97. Kitada, K.; Yui, N.; Matsumoto, C.; Mori, T.; Ohkita, M.; Matsumura, Y. Inhibition of endothelin ETB receptor system aggravates neointimal hyperplasia after balloon injury of rat carotid artery. J Pharmacol Exp Ther, 2009, 331, 998-1004.
98. Loomis, E. D.; Sullivan, J. C.; Osmond, D. A.; Pollock, D. M.; Pollock, J. S. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther, 2005, 315, 1058-1064.
99. Raichlin, E.; Prasad, A.; Mathew, V.; Kent, B.; Holmes, D. R., Jr.; Pumper, G. M.; Nelson, R. E.; Lerman, L. O.; Lerman, A. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension, 2008, 52, 522-528.
100. Prasad, V. S.; Palaniswamy, C.; Frishman, W. H. Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev, 2009, 17, 181-191.
101. Ferro, C. J.; Webb, D. J. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs, 1996, 51, 12-27.
102. Schiffrin, E. L. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens, 2001, 14, 83S-89S.
103. Oishi, S.; Sasaki, M.; Sato, T. Elevated immunoreactive endothelin levels in patients with pheochromocytoma. Am J Hypertens, 1994, 7, 717-722.
104. Saito, I.; Mizuno, K.; Niimura, S.; Fukuchi, S. Urinary endothelin and sodium excretion in essential hypertension. Nephron, 1993, 65, 152-153.
105. Malatino, L. S.; Bellanuova, I.; Cataliotti, A.; Cuzzola, F.; Mallamaci, F.; Tripepi, G.; Parlongo, S.; Cutrupi, S.; Mangiafico, R. A.; Ferri, C.; Galletti, F.; Glorioso, N.; Strazzullo, P.; Zoccali, C. Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. Salt Sensitivity Group of the Italian Society of Hypertension. J Nephrol, 2000, 13, 178-184.
106. Coutinho, T.; Al-Omari, M.; Mosley, T. H., Jr.; Kullo, I. J. Biomarkers of left ventricular hypertrophy and remodeling in blacks. Hypertension, 2011, 58, 920-925.
107. Al-Omari, M. A.; Khaleghi, M.; Mosley, T. H., Jr.; Morgenthaler, N. G.; Struck, J.; Bergmann, A.; Kullo, I. J. Plasma C-terminal proendothelin-1 is associated with left ventricular mass index and aortic root diameter in African-American adults with hypertension. J Hum Hypertens, 2011, 25, 106-113.
108. Nakano, D.; Pollock, D. New concepts in endothelin control of sodium balance. Clin Exp Pharmacol Physiol, 2012, 39, 104-110.
109. Dhaun, N.; Goddard, J.; Kohan, D. E.; Pollock, D. M.; Schiffrin, E. L.; Webb, D. J. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension, 2008, 52, 452-459.
110. Iglarz, M.; Schiffrin, E. L. Role of endothelin-1 in hypertension. Curr Hypertens Rep, 2003, 5, 144-148.
111. Jackson, R. W.; Treiber, F. A.; Harshfield, G. A.; Waller, J. L.; Pollock, J. S.; Pollock, D. M. Urinary excretion of vasoactive factors are correlated to sodium excretion. Am J Hypertens, 2001, 14, 1003-1006.
112. Karet, F. E. Endothelin peptides and receptors in human kidney. Clin Sci (Lond), 1996, 91, 267-273.
113. Terada, Y.; Tomita, K.; Nonoguchi, H.; Marumo, F. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest, 1992, 90, 107-112.
114. Herrera, M.; Hong, N. J.; Ortiz, P. A.; Garvin, J. L. Endothelin-1 inhibits thick ascending limb transport via Akt-stimulated nitric oxide production. J Biol Chem, 2009, 284, 1454-1460.
115. Tomita, K.; Nonoguchi, H.; Terada, Y.; Marumo, F. Effects of ET-1 on water and chloride transport in cortical collecting ducts of the rat. Am J Physiol, 1993, 264, F690-696.
116. Bugaj, V.; Pochynyuk, O.; Mironova, E.; Vandewalle, A.; Medina, J. L.; Stockand, J. D. Regulation of the epithelial Na+ channel by endothelin-1 in rat collecting duct. Am J Physiol Renal Physiol, 2008, 295, F1063-1070.
117. Stricklett, P. K.; Hughes, A. K.; Kohan, D. E. Endothelin-1 stimulates NO production and inhibits cAMP accumulation in rat inner medullary collecting duct through independent pathways. Am J Physiol Renal Physiol, 2006, 290, F1315-1319.
118. Nakano, D.; Pollock, D. M. Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension, 2009, 53, 324-330.
119. Pallone, T. L.; Silldorff, E. P. Pericyte regulation of renal medullary blood flow. Exp Nephrol, 2001, 9, 165-170.
120. Nakano, D.; Pollock, J. S.; Pollock, D. M. Renal medullary ETB receptors produce diuresis and natriuresis via NOS1. Am J Physiol Renal Physiol, 2008, 294, F1205-1211.
121. Kohan, D. E.; Hughes, A. K. Autocrine role of endothelin in rat IMCD: inhibition of AVP-induced cAMP accumulation. Am J Physiol, 1993, 265, F126-129.
122. Herrera, M.; Garvin, J. L. A high-salt diet stimulates thick ascending limb eNOS expression by raising medullary osmolality and increasing release of endothelin-1. Am J Physiol Renal Physiol, 2005, 288, F58-64.
123. Hale, T. M.; Bushfield, T. L.; Woolard, J.; Pang, J. J.; Rees-Milton, K. J.; Adams, M. A. Changes critical to persistent lowering of arterial pressure in spontaneously hypertensive rat occur early in antihypertensive treatment. J Hypertens, 2011, 29, 113-122.
124. Wong, W. H.; Wong, B. P.; Wong, E. F.; Huang, M. H.; Wong, N. L. Downregulation of endothelin B receptors in cardiomyopathic hamsters. Cardiology, 1998, 89, 195-201.
125. Wong, N. L.; Tsui, J. K. Angiotensin regulates endothelin-B receptor in rat inner medullary collecting duct. Metabolism, 2001, 50, 661-666.
126. Kittikulsuth, W.; Pollock, J. S.; Pollock, D. M. Loss of renal medullary endothelin B receptor function during salt deprivation is regulated by angiotensin II. Am J Physiol Renal Physiol, 2012, 303, F659-666.
127. Haynes, W. G.; Ferro, C. J.; O'Kane, K. P.; Somerville, D.; Lomax, C. C.; Webb, D. J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation, 1996, 93, 1860-1870.
128. Rabelink, T. J.; Kaasjager, K. A.; Boer, P.; Stroes, E. G.; Braam, B.; Koomans, H. A. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int, 1994, 46, 376-381.
129. Li, J. S.; Lariviere, R.; Schiffrin, E. L. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension, 1994, 24, 183-188.
130. Pollock, D. M.; Derebail, V. K.; Yamamoto, T.; Pollock, J. S. Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats. Gen Pharmacol, 2000, 34, 337-342.
131. Park, J. B.; Schiffrin, E. L. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension, 2001, 37, 1444-1449.
132. Barton, M.; d'Uscio, L. V.; Shaw, S.; Meyer, P.; Moreau, P.; Luscher, T. F. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension, 1998, 31, 499-504.
133. Touyz, R. M.; Turgeon, A.; Schiffrin, E. L. Endothelin-A-receptor blockade improves renal function and doubles the lifespan of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol, 2000, 36, S300-304.
134. Herizi, A.; Jover, B.; Bouriquet, N.; Mimran, A. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension, 1998, 31, 10-14.
135. Schiffrin, E. L.; Sventek, P.; Li, J. S.; Turgeon, A.; Reudelhuber, T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol, 1995, 115, 1377-1381.
136. Karam, H.; Heudes, D.; Bruneval, P.; Gonzales, M. F.; Loffler, B. M.; Clozel, M.; Clozel, J. P. Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension, 1996, 28, 379-385.
137. Vaneckova, I.; Kramer, H. J.; Backer, A.; Vernerova, Z.; Opocensky, M.; Cervenka, L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension, 2005, 46, 969-974.
138. Vernerova, Z.; Kramer, H. J.; Backer, A.; Cervenka, L.; Opocensky, M.; Huskova, Z.; Vanourkova, Z.; Eis, V.; Chabova, V. C.; Tesar, V.; Maly, J.; Vaneckova, I. Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats. Vascul Pharmacol, 2008, 48, 165-173.
139. Vernerova, Z.; Kujal, P.; Kramer, H. J.; Backer, A.; Cervenka, L.; Vaneckova, I. End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade. Physiol Res, 2009, 58 Suppl 2, S69-78.
140. Krum, H.; Viskoper, R. J.; Lacourciere, Y.; Budde, M.; Charlon, V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med, 1998, 338, 784-790.
141. Nakov, R.; Pfarr, E.; Eberle, S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens, 2002, 15, 583-589.
142. Grassi, G. Selective endothelin receptor blockade in resistant hypertension: results of the DORADO trial. Expert Opin Pharmacother, 2011, 12, 153-155.
143. Weber, M. A.; Black, H.; Bakris, G.; Krum, H.; Linas, S.; Weiss, R.; Linseman, J. V.; Wiens, B. L.; Warren, M. S.; Lindholm, L. H. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet, 2009, 374, 1423-1431.
144. Grieff, M.; Loertscher, R.; Shohaib, S. A.; Stewart, D. J. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation, 1993, 56, 880-884.
145. Haug, C.; Duell, T.; Voisard, R.; Lenich, A.; Kolb, H. J.; Mickley, V.; Hombach, V.; Grunert, A. Cyclosporine A stimulates endothelin release. J Cardiovasc Pharmacol, 1995, 26 Suppl 3, S239-241.
146. Bartholomeusz, B.; Hardy, K. J.; Nelson, A. S.; Phillips, P. A. Bosentan ameliorates cyclosporin A-induced hypertension in rats and primates. Hypertension, 1996, 27, 1341-1345.
147. Plumpton, C.; Haynes, W. G.; Webb, D. J.; Davenport, A. P. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol, 1995, 116, 1821-1828.
148. Dhaun, N.; Webb, D. J. Dual endothelin-converting enzyme/neutral endopeptidase inhibition: a novel treatment for renovascular hypertension beyond blood pressure lowering? Hypertension, 2011, 57, 667-669.
149. Seed, A.; Kuc, R. E.; Maguire, J. J.; Hillier, C.; Johnston, F.; Essers, H.; de Voogd, H. J.; McMurray, J.; Davenport, A. P. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci, 2012, 91, 743-748.
150. Kalk, P.; Sharkovska, Y.; Kashina, E.; von Websky, K.; Relle, K.; Pfab, T.; Alter, M.; Guillaume, P.; Provost, D.; Hoffmann, K.; Fischer, Y.; Hocher, B. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension, 2011, 57, 755-763.
151. Jessup, M.; Brozena, S. Heart failure. N Engl J Med, 2003, 348, 2007-2018.
152. Kiowski, W.; Sutsch, G.; Hunziker, P.; Muller, P.; Kim, J.; Oechslin, E.; Schmitt, R.; Jones, R.; Bertel, O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 1995, 346, 732-736.
153. Pacher, R.; Stanek, B.; Hulsmann, M.; Koller-Strametz, J.; Berger, R.; Schuller, M.; Hartter, E.; Ogris, E.; Frey, B.; Heinz, G.; Maurer, G. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol, 1996, 27, 633-641.
154. Wei, C. M.; Lerman, A.; Rodeheffer, R. J.; McGregor, C. G.; Brandt, R. R.; Wright, S.; Heublein, D. M.; Kao, P. C.; Edwards, W. D.; Burnett, J. C., Jr. Endothelin in human congestive heart failure. Circulation, 1994, 89, 1580-1586.
155. Parker, J. D.; Thiessen, J. J. Increased endothelin-1 production in patients with chronic heart failure. Am J Physiol Heart Circ Physiol, 2004, 286, H1141-1145.
156. Hulsmann, M.; Stanek, B.; Frey, B.; Sturm, B.; Putz, D.; Kos, T.; Berger, R.; Woloszczuk, W.; Maurer, G.; Pacher, R. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol, 1998, 32, 1695-1700.
157. Masson, S.; Latini, R.; Anand, I. S.; Barlera, S.; Judd, D.; Salio, M.; Perticone, F.; Perini, G.; Tognoni, G.; Cohn, J. N. The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail, 2006, 12, 375-380.
158. MacCarthy, P. A.; Grocott-Mason, R.; Prendergast, B. D.; Shah, A. M. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation, 2000, 101, 142-147.
159. Ohmae, M. Endothelin-1 levels in chronic congestive heart failure. Wien Klin Wochenschr, 2011, 123, 714-717.
160. Yin, W. H.; Chen, Y. H.; Wei, J.; Jen, H. L.; Huang, W. P.; Young, M. S.; Chen, D. C.; Liu, P. L. Associations between endothelin-1 and adiponectin in chronic heart failure. Cardiology, 2011, 118, 207-216.
161. Cowburn, P. J.; Cleland, J. G. Endothelin antagonists for chronic heart failure: do they have a role? Eur Heart J, 2001, 22, 1772-1784.
162. Wada, A.; Tsutamoto, T.; Fukai, D.; Ohnishi, M.; Maeda, K.; Hisanaga, T.; Maeda, Y.; Matsuda, Y.; Kinoshita, M. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol, 1997, 30, 1385-1392.
163. Louis, A.; Cleland, J. G.; Crabbe, S.; Ford, S.; Thackray, S.; Houghton, T.; Clark, A. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail, 2001, 3, 381-387.
164. McMurray, J. J.; Teerlink, J. R.; Cotter, G.; Bourge, R. C.; Cleland, J. G.; Jondeau, G.; Krum, H.; Metra, M.; O'Connor, C. M.; Parker, J. D.; Torre-Amione, G.; van Veldhuisen, D. J.; Lewsey, J.; Frey, A.; Rainisio, M.; Kobrin, I. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA, 2007, 298, 2009-2019.
165. Teerlink, J. R.; McMurray, J. J.; Bourge, R. C.; Cleland, J. G.; Cotter, G.; Jondeau, G.; Krum, H.; Metra, M.; O'Connor, C. M.; Parker, J. D.; Torre-Amione, G.; Van Veldhuisen, D. J.; Frey, A.; Rainisio, M.; Kobrin, I. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J, 2005, 150, 46-53.
166. Ryu, S. M.; Kim, H. J.; Cho, K. R.; Jo, W. M. Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models. J Korean Med Sci, 2009, 24, 782-788.
167. Attina, T.; Camidge, R.; Newby, D. E.; Webb, D. J. Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart, 2005, 91, 825-831.
168. Mylona, P.; Cleland, J. G. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Fail, 1999, 1, 197-200.
169. Thackray, S. D.; Witte, K. K.; Khand, A.; Dunn, A.; Clark, A. L.; Cleland, J. G. Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. Eur J Heart Fail, 2001, 3, 117-124.
170. Teerlink, J. R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy? J Card Fail, 2002, 8, 124-127.
171. Anand, I.; McMurray, J.; Cohn, J. N.; Konstam, M. A.; Notter, T.; Quitzau, K.; Ruschitzka, F.; Luscher, T. F. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet, 2004, 364, 347-354.
172. Luscher, T. F.; Barton, M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation, 2000, 102, 2434-2440.
173. Leslie, S. J.; Spratt, J. C.; McKee, S. P.; Strachan, F. E.; Newby, D. E.; Northridge, D. B.; Denvir, M. A.; Webb, D. J. Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart, 2005, 91, 914-919.
174. Givertz, M. M.; Colucci, W. S.; LeJemtel, T. H.; Gottlieb, S. S.; Hare, J. M.; Slawsky, M. T.; Leier, C. V.; Loh, E.; Nicklas, J. M.; Lewis, B. E. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation, 2000, 101, 2922-2927.
175. Kaluski, E.; Cotter, G.; Leitman, M.; Milo-Cotter, O.; Krakover, R.; Kobrin, I.; Moriconi, T.; Rainisio, M.; Caspi, A.; Reizin, L.; Zimlichman, R.; Vered, Z. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study. Cardiology, 2008, 109, 273-280.
176. Jiang, B. H.; Tardif, J. C.; Shi, Y.; Dupuis, J. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J, 2011, 37, 578-586.
177. Cowburn, P. J.; Cleland, J. G.; McDonagh, T. A.; McArthur, J. D.; Dargie, H. J.; Morton, J. J. Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail, 2005, 7, 37-42.
178. Nguyen, Q. T.; Cernacek, P.; Sirois, M. G.; Calderone, A.; Lapointe, N.; Stewart, D. J.; Rouleau, J. L. Long-term effects of nonselective endothelin A and B receptor antagonism in postinfarction rat: importance of timing. Circulation, 2001, 104, 2075-2081.
179. Schirger, J. A.; Chen, H. H.; Jougasaki, M.; Lisy, O.; Boerrigter, G.; Cataliotti, A.; Burnett, J. C., Jr. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention. Circulation, 2004, 109, 249-254.
180. Wada, A.; Tsutamoto, T.; Ohnishi, M.; Sawaki, M.; Fukai, D.; Maeda, Y.; Kinoshita, M. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Circulation, 1999, 99, 570-577.
181. Rufanova, V. A.; Pozdnev, V. F.; Kalenikova, E. I.; Postnikov, A. B.; Storozhilova, A. N.; Masenko, V. P.; Gomazkov, O. A.; Medvedev, O. S.; Medvedeva, N. A. Endothelin-converting enzyme inhibition in the rat model of acute heart failure: heart function and neurohormonal activation. Exp Biol Med (Maywood), 2009, 234, 1201-1211.
182. Ono, K.; Tsujimoto, G.; Sakamoto, A.; Eto, K.; Masaki, T.; Ozaki, Y.; Satake, M. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature, 1994, 370, 301-304.
183. Duru, F.; Barton, M.; Luscher, T. F.; Candinas, R. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res, 2001, 49, 272-280.
184. Mackenzie, L.; Bootman, M. D.; Laine, M.; Berridge, M. J.; Thuring, J.; Holmes, A.; Li, W. H.; Lipp, P. The role of inositol 1,4,5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol, 2002, 541, 395-409.
185. Li, X.; Zima, A. V.; Sheikh, F.; Blatter, L. A.; Chen, J. Endothelin-1-induced arrhythmogenic Ca2+ signaling is abolished in atrial myocytes of inositol-1,4,5-trisphosphate(IP3)-receptor type 2-deficient mice. Circ Res, 2005, 96, 1274-1281.
186. Latini, R.; Masson, S.; Pirelli, S.; Barlera, S.; Pulitano, G.; Carbonieri, E.; Gulizia, M.; Vago, T.; Favero, C.; Zdunek, D.; Struck, J.; Staszewsky, L.; Maggioni, A. P.; Franzosi, M. G.; Disertori, M. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial. J Intern Med, 2011, 269, 160-171.
187. Nakazawa, Y.; Ashihara, T.; Tsutamoto, T.; Ito, M.; Horie, M. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm, 2009, 6, 725-730.
188. Humbert, M.; Morrell, N. W.; Archer, S. L.; Stenmark, K. R.; MacLean, M. R.; Lang, I. M.; Christman, B. W.; Weir, E. K.; Eickelberg, O.; Voelkel, N. F.; Rabinovitch, M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol, 2004, 43, 13S-24S.
189. Humbert, M.; Sitbon, O.; Simonneau, G. Treatment of pulmonary arterial hypertension. N Engl J Med, 2004, 351, 1425-1436.
190. Gomberg-Maitland, M.; Dufton, C.; Oudiz, R. J.; Benza, R. L. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol, 2011, 57, 1053-1061.
191. Dupuis, J.; Stewart, D. J.; Cernacek, P.; Gosselin, G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation, 1996, 94, 1578-1584.
192. Stewart, D. J.; Levy, R. D.; Cernacek, P.; Langleben, D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med, 1991, 114, 464-469.
193. Cody, R. J.; Haas, G. J.; Binkley, P. F.; Capers, Q.; Kelley, R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation, 1992, 85, 504-509.
194. Giaid, A.; Stewart, D. J.; Michel, R. P. Endothelin-1-like immunoreactivity in postobstructive pulmonary vasculopathy. J Vasc Res, 1993, 30, 333-338.
195. Ishikawa, S.; Miyauchi, T.; Sakai, S.; Ushinohama, H.; Sagawa, K.; Fusazaki, N.; Kado, H.; Sunagawa, H.; Honda, S.; Ueno, H.; et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J Thorac Cardiovasc Surg, 1995, 110, 271-273.
196. Kim, H.; Yung, G. L.; Marsh, J. J.; Konopka, R. G.; Pedersen, C. A.; Chiles, P. G.; Morris, T. A.; Channick, R. N. Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Exp Lung Res, 2000, 26, 287-301.
197. Clozel, M.; Salloukh, H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med, 2005, 37, 2-12.
198. Rubens, C.; Ewert, R.; Halank, M.; Wensel, R.; Orzechowski, H. D.; Schultheiss, H. P.; Hoeffken, G. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest, 2001, 120, 1562-1569.
199. Heresi, G. A. Clinical perspective: biomarkers in pulmonary arterial hypertension. Int J Clin Pract Suppl, 2011, 5-7.
200. Hay, D. W.; Henry, P. J.; Goldie, R. G. Endothelin and the respiratory system. Trends Pharmacol Sci, 1993, 14, 29-32.
201. Maguire, J. J.; Davenport, A. P. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol, 1995, 115, 191-197.
202. McCulloch, K. M.; Docherty, C. C.; Morecroft, I.; MacLean, M. R. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol, 1996, 119, 1125-1130.
203. Russell, F. D.; Davenport, A. P. Characterization of endothelin receptors in the human pulmonary vasculature using bosentan, SB209670, and 97-139. J Cardiovasc Pharmacol, 1995, 26 Suppl 3, S346-347.
204. Adner, M.; Cardell, L. O.; Sjoberg, T.; Ottosson, A.; Edvinsson, L. Contractile endothelin-B (ETB) receptors in human small bronchi. Eur Respir J, 1996, 9, 351-355.
205. Takahashi, T.; Barnes, P. J.; Kawikova, I.; Yacoub, M. H.; Warner, T. D.; Belvisi, M. G. Contraction of human airway smooth muscle by endothelin-1 and IRL 1620: effect of bosentan. Eur J Pharmacol, 1997, 324, 219-222.
206. Hay, D. W.; Luttmann, M. A.; Pullen, M. A.; Nambi, P. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype? J Pharmacol Exp Ther, 1998, 284, 669-677.
207. Rubin, L. J.; Badesch, D. B.; Barst, R. J.; Galie, N.; Black, C. M.; Keogh, A.; Pulido, T.; Frost, A.; Roux, S.; Leconte, I.; Landzberg, M.; Simonneau, G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 2002, 346, 896-903.
208. Sitbon, O.; Badesch, D. B.; Channick, R. N.; Frost, A.; Robbins, I. M.; Simonneau, G.; Tapson, V. F.; Rubin, L. J. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest, 2003, 124, 247-254.
209. McLaughlin, V. V.; Sitbon, O.; Badesch, D. B.; Barst, R. J.; Black, C.; Galie, N.; Rainisio, M.; Simonneau, G.; Rubin, L. J. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J, 2005, 25, 244-249.
210. Galie, N.; Rubin, L.; Hoeper, M.; Jansa, P.; Al-Hiti, H.; Meyer, G.; Chiossi, E.; Kusic-Pajic, A.; Simonneau, G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet, 2008, 371, 2093-2100.
211. Gruenig, E.; Michelakis, E.; Vachiery, J. L.; Vizza, C. D.; Meyer, F. J.; Doelberg, M.; Bach, D.; Dingemanse, J.; Galie, N. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol, 2009, 49, 1343-1352.
212. Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH) (Compass 2). http://clinicaltrials.gov/ct2/show/record/NCT00303459 (Accessed December 13, 2012).
213. Humbert, M.; Barst, R. J.; Robbins, I. M.; Channick, R. N.; Galie, N.; Boonstra, A.; Rubin, L. J.; Horn, E. M.; Manes, A.; Simonneau, G. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J, 2004, 24, 353-359.
214. McLaughlin, V. V.; Oudiz, R. J.; Frost, A.; Tapson, V. F.; Murali, S.; Channick, R. N.; Badesch, D. B.; Barst, R. J.; Hsu, H. H.; Rubin, L. J. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2006, 174, 1257-1263.
215. Galie, N.; Badesch, D.; Oudiz, R.; Simonneau, G.; McGoon, M. D.; Keogh, A. M.; Frost, A. E.; Zwicke, D.; Naeije, R.; Shapiro, S.; Olschewski, H.; Rubin, L. J. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol, 2005, 46, 529-535.
216. Galie, N.; Olschewski, H.; Oudiz, R. J.; Torres, F.; Frost, A.; Ghofrani, H. A.; Badesch, D. B.; McGoon, M. D.; McLaughlin, V. V.; Roecker, E. B.; Gerber, M. J.; Dufton, C.; Wiens, B. L.; Rubin, L. J. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation, 2008, 117, 3010-3019.
217. Barst, R. J.; Langleben, D.; Frost, A.; Horn, E. M.; Oudiz, R.; Shapiro, S.; McLaughlin, V.; Hill, N.; Tapson, V. F.; Robbins, I. M.; Zwicke, D.; Duncan, B.; Dixon, R. A.; Frumkin, L. R. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 2004, 169, 441-447.
218. Barst, R. J.; Langleben, D.; Badesch, D.; Frost, A.; Lawrence, E. C.; Shapiro, S.; Naeije, R.; Galie, N. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol, 2006, 47, 2049-2056.
219. Available at: http://www.pfizer.com/news/press_releases/pfizer_press_release_archive.jsp#guid=22387&source=RSS_2010&page=1 (Accessed 9 December, 2012).
220. Sidharta, P. N.; van Giersbergen, P. L.; Halabi, A.; Dingemanse, J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol, 2011, 67, 977-984.
221. Gatfield, J.; Mueller Grandjean, C.; Sasse, T.; Clozel, M.; Nayler, O. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One, 2012, 7, e47662.
222. Bolli, M. H.; Boss, C.; Binkert, C.; Buchmann, S.; Bur, D.; Hess, P.; Iglarz, M.; Meyer, S.; Rein, J.; Rey, M.; Treiber, A.; Clozel, M.; Fischli, W.; Weller, T. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem, 2012, 55, 7849-7861.